Thunder and lightning: immunotherapy and oncolytic viruses collide - PubMed (original) (raw)

Review

. 2011 Jun;19(6):1008-16.

doi: 10.1038/mt.2011.65. Epub 2011 Apr 19.

Affiliations

Review

Thunder and lightning: immunotherapy and oncolytic viruses collide

Alan Melcher et al. Mol Ther. 2011 Jun.

Abstract

For the last several decades, the development of antitumor immune-based strategies and the engineering and testing of oncolytic viruses (OVs) has occurred largely in parallel tracks. Indeed, the immune system is often thought of as an impediment to successful oncolytic virus delivery and efficacy. More recently, however, both preclinical and clinical results have revealed potential synergy between these two promising therapeutic strategies. Here, we summarize some of the evidence that supports combining OVs with immuno-therapeutics and suggest new ways to mount a multipronged biological attack against cancers.

PubMed Disclaimer

Figures

Figure 1

Figure 1

It takes two to tango: striking the balance between antitumor activity, and antivector immunity. (a) Immune barriers to oncolytic virus (OV) delivery/spread. (b) Antitumor immune activity. (c) Blockade/suppression of immune activity. CAR, chimeric antigen receptor; CTL, cytotoxic T lymphocyte; DC, dendritic cell; IDO, indoleamine 2,3-dioxygenase; IFN, interferon; IL, interleukin; MHC, major histocompatibility complex; NK, natural killer cell; TGF-β, transforming growth factor-β TIL, tumor infiltrating lymphocyte; VEGF, vascular endothelial growth factor.

Figure 2

Figure 2

Combining oncolytic virotherapy with tumor-specific T cells. Oncolytic virus (OV)-specific T cells could be expanded ex vivo after the second vaccination. If the individual was already exposed to the OV by vaccination or prior infection, then the T cells could be manufactured earlier. After activation, the T cells could be transduced with a retroviral vector expressing a tumor-specific chimeric antigen receptor (CAR) to redirect their specificity to a tumor antigen. The transduced cytotoxic T lymphocytes (CTLs) could then be infused after virotherapy when the tumor load would be reduced. The OV could then be used as a vaccine to induce T-cell expansion and maintain function.

Similar articles

Cited by

References

    1. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P.et al. (2008Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 3211801–1806. - PMC - PubMed
    1. Subarsky P., and, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis. 2003;20:237–250. - PubMed
    1. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT.et al. (2009The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research Clin Cancer Res 155323–5337. - PMC - PubMed
    1. Kim M, Williamson CT, Prudhomme J, Bebb DG, Riabowol K, Lee PW.et al. (2010The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status Oncogene 293990–3996. - PMC - PubMed
    1. Ramírez M, García-Castro J., and, Alemany R. Oncolytic virotherapy for neuroblastoma. Discov Med. 2010;10:387–393. - PubMed

Publication types

MeSH terms

LinkOut - more resources